Teleflex Incorporated (NYSE:TFX) Director Purchases $115,250.00 in Stock

Key Points

• Director Andrew A. Krakauer purchased 1,000 shares of Teleflex stock for $115.25 per share, totaling $115,250, increasing his position by 16.15% to a total of 7,192 shares.
• Teleflex reported earnings of $3.73 per share for the last quarter, surpassing analysts' expectations of $3.36 and achieving a revenue of $780.90 million.
• The company declared a quarterly dividend of $0.34 per share, scheduled to be paid on September 15, which reflects an annualized dividend of $1.36 and a yield of 1.2%.

Teleflex Incorporated (NYSE:TFX - Get Free Report) Director Andrew A. Krakauer bought 1,000 shares of Teleflex stock in a transaction dated Tuesday, August 5th. The stock was purchased at an average cost of $115.25 per share, with a total value of $115,250.00. Following the completion of the acquisition, the director directly owned 7,192 shares in the company, valued at approximately $828,878. The trade was a 16.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Teleflex Price Performance

NYSE:TFX traded up $3.35 during trading hours on Thursday, hitting $115.42. The company's stock had a trading volume of 694,762 shares, compared to its average volume of 807,305. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. Teleflex Incorporated has a 52-week low of $108.90 and a 52-week high of $249.90. The business's 50-day moving average is $118.48 and its two-hundred day moving average is $135.98. The company has a market capitalization of $5.10 billion, a PE ratio of 27.16, a PEG ratio of 1.60 and a beta of 1.08.

Teleflex (NYSE:TFX - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.36 by $0.37. The company had revenue of $780.90 million during the quarter, compared to analysts' expectations of $771.53 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the company posted $3.42 earnings per share. As a group, research analysts anticipate that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 15th will be given a $0.34 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.2%. Teleflex's dividend payout ratio (DPR) is currently 32.00%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TFX. Pzena Investment Management LLC purchased a new position in Teleflex during the 2nd quarter valued at about $42,149,000. Dimensional Fund Advisors LP grew its position in shares of Teleflex by 69.5% in the first quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company's stock valued at $119,927,000 after purchasing an additional 355,720 shares during the last quarter. Invesco Ltd. increased its stake in shares of Teleflex by 48.1% during the 4th quarter. Invesco Ltd. now owns 1,068,593 shares of the medical technology company's stock worth $190,188,000 after purchasing an additional 347,003 shares in the last quarter. Diamond Hill Capital Management Inc. raised its position in shares of Teleflex by 122.8% during the 1st quarter. Diamond Hill Capital Management Inc. now owns 584,586 shares of the medical technology company's stock worth $80,784,000 after purchasing an additional 322,222 shares during the last quarter. Finally, Invenomic Capital Management LP lifted its stake in Teleflex by 1,400.1% in the 1st quarter. Invenomic Capital Management LP now owns 344,732 shares of the medical technology company's stock valued at $47,639,000 after buying an additional 321,751 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company's stock.

Analyst Ratings Changes

TFX has been the subject of a number of research reports. Wells Fargo & Company reduced their price objective on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Wall Street Zen raised shares of Teleflex from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Royal Bank Of Canada upped their target price on shares of Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a report on Friday, August 1st. Truist Financial lowered their price target on Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a report on Monday, May 5th. Finally, Morgan Stanley lowered their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research note on Monday, May 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Teleflex presently has an average rating of "Hold" and an average target price of $141.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.